HPV疫苗接种规划对男男性行为者肛门HPV感染的影响:英格兰多站点强化监测研究
研究评估英格兰2016年启动的男男性行为者(GBMSM)HPV疫苗接种规划效果,在10个性健康服务站点收集2017-19年(第一阶段)和2021-24年(第二阶段)≤45岁GBMSM的直肠拭子残留标本,检测型别特异性HPV DNA。共分析5787份标本,两阶段间肛门HPV16/18感染率下降36%;有报告接种与无报告接种者HPV16/18感染率相近(16.6% vs 15.8%)。结论认为接种启动八年后疫苗型HPV感染率下降,但数据无法准确估计疫苗效果。
要点
- 两阶段间肛门HPV16/18感染率下降36%。
- 有报告接种者HPV16/18感染率为16.6%(95%CI 15.2-18.1)。
- 无报告接种者HPV16/18感染率为15.8%(95%CI 14.5-17.1)。
核心结论
- HPV疫苗接种规划启动八年后,GBMSM中疫苗型HPV感染率下降,但现有数据无法准确估计疫苗效果。
研究设计与样本
- 多站点强化监测研究,在英格兰10个性健康服务站点收集≤45岁GBMSM的直肠拭子残留标本,分2017-19年(第一阶段)和2021-24年(第二阶段)两期。
- 共分析5787份有HPV检测结果的直肠拭子标本,第一阶段3291份,第二阶段2496份。
- 标本匿名化后用内部多重PCR和Luminex基因分型检测型别特异性HPV DNA,并链接国家STI监测系统的社会人口学、既往STI诊断和HPV接种报告数据。
主要发现
- 两阶段间肛门HPV16/18感染率下降36%。
- 有报告HPV接种者HPV16/18感染率为16.6%(95%CI 15.2-18.1),无报告接种者为15.8%(95%CI 14.5-17.1),两者相近。
临床怎么用
- 监测结果提示该靶向接种规划可能有助于降低GBMSM中HPV相关疾病,但个体接种史报告不完整,解读接种与感染关系需谨慎。
局限性
- 现有数据无法准确估计疫苗效果,可能受接种报告不足、群体保护和接种 uptake 偏倚的共同影响。
- 研究结果属于生态学性质。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A national human papillomavirus (HPV) vaccination programme for gay, bisexual, and other men who have sex with men (GBMSM) in England began in 2016. We evaluated the impact of this programme by monitoring the prevalence of type-specific HPV infections over time. METHODS: Residual rectal swab specimens were collected from GBMSM aged ≤45 years undergoing chlamydia and/or gonorrhoea screening at 10 sexual health services (SHSs) between 2017-19 (Phase 1) and 2021-24 (Phase 2). Specimens were linked to data on sociodemographic characteristics, previous STI diagnoses, and HPV vaccination reported to the UK Health Security Agency's (UKHSA's) national STI surveillance system. Anonymised specimens were tested for type-specific HPV DNA using an in-house multiplex PCR and Luminex-based genotyping test. We compared the prevalence of vaccine-type HPV in each phase, and in those with and without any reported HPV vaccinations. RESULTS: Data from 5,787 rectal swab specimens with HPV testing results were analysed: 3,291 in Phase 1 and 2,496 in Phase 2. There was a 36% decline in the prevalence of anal HPV16/18 infection between Phase 1 and Phase 2. Overall, the prevalence of HPV16/18 was similar in GBMSM with (16.6%; 95% CI 15.2-18.1) and without reported HPV vaccination (15.8%; 95% CI 14.5-17.1). CONCLUSION: Eight years after HPV vaccination of GBMSM began, the prevalence of vaccine-type HPV in GBMSM has declined. Available data did not permit accurate estimation of vaccine effectiveness, likely due to the combined effects of underreporting of vaccinations, herd protection, and bias in vaccination uptake. These findings, albeit ecological, bode well for this targeted programme meeting its aim of reducing HPV-related diseases among GBMSM and reducing health inequalities.
引用
- Checchi M, Panwar K, French CE, et al. Impact of the HPV vaccination programme on anal HPV infection in gay, bisexual and other men who have sex with men: multi-site enhanced surveillance study in specialist sexual health services in England. Vaccine. 2026. PMID: 42702144. doi:10.1016/j.vaccine.2026.129114
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。